Integrated analysis confirms decision to remove Entresto® from UM
April 1, 2020
Unique cost of care study on sacubitril-valsartan (sac-val) shows significant medical cost savings for adherent users; also, advanced analytics adds insights to impact UM for all users
Heart failure is the leading cause of death in the U.S. Sac-val is proven to decrease hospitalization and reduce death due to heart failure with reduced ejection fraction (HFrEF), also known as systolic heart failure.
As a knowledge management company, Prime wanted to study real world integrated benefits data on use of sac-val for adherent members, as well as all sac-val utilizing members.
This study looked at more than 1,000 members newly initiating sac-val. For an adherent members taking sac-val, after just one year:
- Medical costs decreased 38%
- Hospital costs decreased 69%
- Emergency room costs decreased 44%
- Total cost of care decreased 22%
When looking at the entire cohort (including adherent and nonadherent members), the cohort still showed a small total decrease in cost of care (2%). Prime’s recommendation to its health plan clients is to offer sac-val on an open formulary. Eliminating the prior authorization fast-tracks member access. This can save lives and health care costs.
August 21, 2021
CAR-T treatment costs more than the CAR-T product itself; Prime’s real-world study of…
August 1, 2021
Insights from integrated medical and pharmacy claims show a big upswing in one…
June 21, 2021
Prime uses integrated medical and pharmacy data and breaks down largest drug category…